NAD⁺ Precursors in 2026: What the Controlled Human Trials Actually Show

For laboratory research use only. Not for human or veterinary use. Not a medicinal product.

What is NAD⁺ and why does it matter in metabolic research?

Nicotinamide adenine dinucleotide (NAD⁺) is a pyridine dinucleotide coenzyme that functions as an electron carrier in cellular redox biochemistry and as a co-substrate for a broad class of signalling enzymes, including sirtuins (SIRT1–7), poly(ADP-ribose) polymerases (PARPs), and cyclic ADP-ribose synthases (CD38/CD157). It occupies a structurally central position in metabolism: without adequate NAD⁺, the oxidation of glucose, fatty acids, and amino acids stalls at the level of key dehydrogenase complexes.

Research interest in NAD⁺ has intensified markedly over the past decade, driven by the observation — well-replicated in rodent models and now documented in human cohorts — that tissue and whole-blood NAD⁺ concentrations appear to fall as biological age advances. This pattern has prompted substantial investigation into whether exogenously supplied precursors can be used to modulate intracellular NAD⁺ pools in research models, and what the functional consequences of such modulation might be. The full scope of current mechanistic and trial data is collated in the NAD⁺ — Evidence Dossier.

How is NAD⁺ biosynthesised, and where do precursors enter the pathway?

NAD⁺ is synthesised via three converging routes: the de novo pathway from tryptophan (the Preiss–Handler route via quinolinic acid), and two salvage pathways from nicotinamide (NAM) and from nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN). The salvage pathway from NAM is quantitatively dominant in most mammalian tissues and is rate-limited by nicotinamide phosphoribosyltransferase (NAMPT).

NR enters the salvage cycle by conversion to NMN via nicotinamide riboside kinases 1 and 2 (NRK1/NRK2), while NMN is converted directly to NAD⁺ by NMN adenylyltransferases (NMNAT1–3). The debate over whether a dedicated NMN transporter (proposed candidate: Slc12a8) permits direct cellular uptake of intact NMN — or whether extracellular NMN is first dephosphorylated to NR before uptake — remains open in the published literature and represents one of the mechanistically significant open questions that distinguishes NMN from NR as research tools.

What do the controlled human trials on NR actually show?

Controlled human research on NR is the more mature of the two precursor literatures. Randomised, double-blind, placebo-controlled trials have consistently demonstrated that oral NR is bioavailable and produces measurable elevation of whole-blood NAD⁺ and its metabolites (NAAD, ADPR, and MeNAM) within days of initiation.

Trammell et al. (2016) published foundational pharmacokinetic data showing dose-dependent rises in blood NAD⁺ metabolites following NR supplementation in healthy adults [VERIFY DOI]. The JAMA Network Open VITAL trial by Elhassan et al. (2019) [VERIFY DOI] examined NR at 1,000 mg per day in older adults over 12 weeks and documented elevated skeletal muscle NAD⁺ concentrations alongside shifts in muscle SIRT1/SIRT3 protein abundance. Notably, no corresponding changes in primary metabolic endpoints (insulin sensitivity, mitochondrial function by respirometry) reached significance, which the authors contextualised as a dissociation between biomarker and functional response — a recurring theme in the field.

Subsequent work by Martens et al. (2018) [VERIFY] in middle-aged and older adults reported that NR at 500 mg twice daily over six weeks elevated blood NAD⁺ by approximately 60% relative to baseline. This study additionally observed a nominally significant reduction in aortic stiffness in a subgroup, though the authors noted the finding required replication in larger cohorts before conclusions could be drawn.

What do the controlled human trials on NMN actually show?

The human NMN trial literature developed somewhat later than NR but has expanded considerably since 2020. Yoshino et al. (2021, Science) [VERIFY DOI] conducted a randomised, placebo-controlled, double-blind crossover trial in postmenopausal women with prediabetes, finding that NMN at 250 mg per day over 10 weeks raised skeletal muscle NAD⁺ biosynthesis (measured by stable-isotope tracing) and was associated with upregulation of genes related to muscle remodelling and insulin signalling. The magnitude of NAD⁺ elevation was substantial, and muscle biopsy data provided a degree of tissue specificity not always achievable via blood-based measures alone.

A separate randomised trial by Igarashi et al. (2022) [VERIFY DOI] in older men found NMN at 250 mg per day for 12 weeks associated with improved gait speed and grip strength in a subgroup analysis — though as a secondary endpoint in a relatively small cohort, this finding remains hypothesis-generating rather than confirmatory.

Liao et al. (2021) [VERIFY DOI] examined NMN in amateur runners, reporting that blood NAD⁺ elevation was accompanied by shifts in aerobic capacity markers at certain submaximal workloads. The mechanistic interpretation of these findings is ongoing, and the research community continues to interrogate whether blood NAD⁺ reliably mirrors tissue-specific NAD⁺ compartments.

How do NMN and NR compare as research tools?

Both precursors reliably raise blood NAD⁺ in human research subjects, but they differ in several dimensions relevant to experimental design. The table below summarises the key distinguishing parameters across the current literature.

All data refer to research subjects in controlled trials; all compounds are for in vitro and laboratory research use only.

What are the key mechanistic uncertainties that remain in 2026?

Despite a maturing evidence base, the NAD⁺ precursor literature contains several unresolved mechanistic questions that make this an active and productive area of inquiry.

Compartmentalisation. Whole-blood NAD⁺ measurements are primarily a reflection of erythrocyte and PBMC pools. The extent to which oral precursor supplementation alters NAD⁺ in metabolically active compartments — liver, brown adipose tissue, the CNS — remains incompletely mapped in humans. Positron emission tomography and isotope tracing approaches are beginning to address this gap.

SIRT1 and PARP1 substrate saturation. Sirtuins and PARPs are enzymes with defined Km values for NAD⁺. Whether the NAD⁺ concentrations achieved in precursor trials meaningfully alter the kinetics of these enzymes in vivo — rather than simply shifting a substrate pool — requires deeper mechanistic investigation.

CD38 as a sink. CD38 is an NADase that consumes NAD⁺ and whose expression rises with age and inflammatory signalling. Research into whether CD38 inhibition (e.g., using 5-Amino-1MQ, an NNMT inhibitor studied in related metabolic contexts — see New Research-Grade 5-Amino-1MQ for NNMT Studies) can modulate the NAD⁺ landscape in ways complementary to precursor loading is an emerging area.

Long-term NAD⁺ metabolomics. Most trials run 6–12 weeks. How chronic precursor exposure affects the broader NAD⁺ metabolome — including the methyl donor burden (MeNAM excretion) and the NAD⁺/NADH ratio in specific tissues — requires longitudinal data sets currently not available.

What quality standards should researchers apply when sourcing NAD⁺ for in vitro work?

Researchers require verified purity documentation before incorporating any compound into in vitro workflows. Contaminants in nominally pure NAD⁺ preparations — including residual nicotinamide, NADH, or synthesis by-products — can confound enzymatic assays, metabolomics readouts, and SIRT1/PARP activity measurements. For guidance on evaluating supplier documentation, the article Research Peptides UK: What They Are, How They're Tested & What to Look For provides a useful framework applicable to small-molecule research compounds. Nexyra Lab publishes independent certificates of analysis accessible via the Certificate of Analysis & Lab Reports page.

If your laboratory workflow involves reconstitution of lyophilised compounds, the How to Reconstitute Research Peptides: Step-by-Step Guide with Bacteriostatic Water resource outlines validated handling procedures, with Bacteriostatic Water (BAC Water) available for reconstitution work.

Research Disclaimer

All Nexyra Lab products are for in vitro research and laboratory use by qualified researchers only. They are not approved by the MHRA, FDA, EMA, or any regulatory authority for human or veterinary use. This article summarises published scientific literature for research planning purposes only and does not constitute medical advice.